Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.
Megen C WittlingHannah M KnochelmannMegan M WyattGuillermo O Rangel RiveraAnna C ColeGregory B LesinskiChrystal M PaulosPublished in: Journal for immunotherapy of cancer (2024)
based T-cell therapies are now emerging in the clinic.